Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

PHASE4RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

July 26, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Atrial FibrillationHeart FailureDiastolic Heart Failure
Interventions
DEVICE

Catheter ablation

Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature

DRUG

Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation

Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation

DEVICE

Insertion of CardioMems Hemodynamic monitor

Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.

DRUG

Empiric heart failure drug therapy

Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.

Trial Locations (9)

1205

RECRUITING

Hopitaux Universitaires de Geneve, Geneva

19104

RECRUITING

Hospital of the University of Pennsylvania, Philadelphia

66211

RECRUITING

Kansas City Heart Rhythm Institute, Overland

72401

RECRUITING

St. Bernards Heart and Vascular Center, Jonesboro

78705

RECRUITING

TCAI at St. David's Hospital, Austin

80120

RECRUITING

South Denver Cardiology, Littleton

81379

NOT_YET_RECRUITING

Peter Osypka Herzzentrum, Munich

86001

RECRUITING

Northern Arizona Health Care, Flagstaff

07059

RECRUITING

Electrophysiology Research Foundation, Warren Township

All Listed Sponsors
lead

Electrophysiology Research Foundation

OTHER